Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-09
2007-01-09
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S490000, C548S492000
Reexamination Certificate
active
11335233
ABSTRACT:
This invention provides indole oxo-acetyl amino acetic acid derivatives which are useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) useful for treating fibrinolytic disorders, the compounds having the structure:wherein: R1is alkyl or optionally substituted cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2is hydrogen, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3is hydrogen, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl; R8is hydrogen, alkyl, cycloalkyl, —CH2-cycloalkyl, perfluoroalkyl, aryl, substituted aryl, alkyl-aryl, or substituted alkyl-aryl; R9is hydrogen, alkyl, hydroxyalkyl, 4-hydroxybenzyl, 3-indolylymethylene, 4-imidazolylmethylene, HSCH2—, CH3SCH2CH2—, H2NC(═O)CH2—, H2NC(═O)CH2CH2—, HO2CCH2—, HO2CCH2CH2—, H2NCH2CH2CH2CH2—, H2NC(═NH)NHCH2CH2CH2—, or taken together with R8as —CH2CH2CH2—; or a pharmaceutically acceptable salt or ester form thereof.
REFERENCES:
patent: 3843683 (1974-10-01), Bell
patent: 4736043 (1988-04-01), Michel et al.
patent: 4851406 (1989-07-01), Martens et al.
patent: 5612360 (1997-03-01), Boyd et al.
patent: 6048875 (2000-04-01), De Nanteuil et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6232327 (2001-05-01), Nickel et al.
patent: 6251936 (2001-06-01), Wrobel et al.
patent: 6302837 (2001-10-01), De Nanteuil et al.
patent: 6787556 (2004-09-01), Hargreaves et al.
patent: 6800645 (2004-10-01), Cox et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6844358 (2005-01-01), Malamas et al.
patent: 2003/0060497 (2003-03-01), Gerlach
patent: 2004/0204417 (2004-10-01), Perez et al.
patent: 43 38 770 (1995-05-01), None
patent: 19543639 (1997-05-01), None
patent: 19753522 (1999-06-01), None
patent: 0 416 609 (1991-03-01), None
patent: 0 508 723 (1992-10-01), None
patent: 0 512 570 (1992-11-01), None
patent: 0 540 956 (1993-05-01), None
patent: 0 655 439 (1995-05-01), None
patent: 0 819 686 (1998-01-01), None
patent: 0 955 299 (1999-11-01), None
patent: 1 092 716 (2001-04-01), None
patent: 1 156 045 (2001-11-01), None
patent: 1 321 433 (1973-06-01), None
patent: 94/14434 (1994-07-01), None
patent: 94/26738 (1994-11-01), None
patent: 95/10513 (1995-04-01), None
patent: 96/06840 (1996-03-01), None
patent: 96/21656 (1996-07-01), None
patent: 96/26207 (1996-08-01), None
patent: 96/32379 (1996-10-01), None
patent: 97/09308 (1997-03-01), None
patent: 97/43260 (1997-11-01), None
patent: 97/48697 (1997-12-01), None
patent: 98/08818 (1998-03-01), None
patent: 99/28297 (1999-06-01), None
patent: 99/43651 (1999-09-01), None
patent: 99/43654 (1999-09-01), None
patent: 99/43672 (1999-09-01), None
patent: 99/46260 (1999-09-01), None
patent: 99/50268 (1999-10-01), None
patent: 99/58519 (1999-11-01), None
patent: 99/61435 (1999-12-01), None
patent: 00/32180 (2000-06-01), None
patent: 00/35919 (2000-06-01), None
patent: 00/46195 (2000-08-01), None
patent: 00/046197 (2000-08-01), None
patent: 01/12187 (2001-02-01), None
patent: 02/030895 (2002-04-01), None
patent: 02/072549 (2002-09-01), None
patent: 03/000253 (2003-01-01), None
patent: 03/031409 (2003-04-01), None
patent: 03/068742 (2003-08-01), None
patent: 03/087087 (2003-10-01), None
patent: 2004/052854 (2004-06-01), None
Albers, G. W., “Advances in intravenous thrombolytic therapy for treatment of acute stroke,”Neurology, 2001, 57(5 Suppl 2), S77-S81.
Ashitani, J. et al., “Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease,”Internal Medicine,Mar. 2002, 41(3), 181-185.
Atiomo, W. U. et al., “Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries,”Gynecological Endocrinology,Jun. 2000, 14(3), 162-168.
Aznar, J. et al., “Role of Plasminogen Activator Inhibitor Type 1 in the Pathogenesis of Coronary Artery Diseases,”Haemostasis24: 243-251 (1994).
Berry, C. N. et al., “Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis,”British Journal of Pharmacology,Sep. 1998, 125(1), 29-34.
Biemond, B. J. et al., “Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis,”Circulation,91: 1175-1181 (1995).
Billgren, A. M. et al., “The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen,”European Journal of Cancer,Jul. 2000, 36(11), 1374-1380.
Carmeliet, P. et al., “Plasminogen Activator Inhibitor—1 Gene-deficient Mice,”Journal of Clinical Investigation,92: 2756-2760 (Dec. 1993).
Charlton, Peter, “The status of plasminogen activator inhibitor-1 as a therapeutic target,” ExpertOpinion On Investigational Drugs,(May 1997), vol. 6, No. 5, pp. 539-554.
Crandall, D. L. et al., “Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy,”Journal of Thrombosis and Haemostasis,Mar. 17, 2004, 2: 1422-1428.
Da Settimo, A. et al., “Reaction of indole derivatives with bromine, substitution, oxidation, and dimerization,”J Org Chem,1970, 35(8):2546-2551.
Daci, E. et al., “Mice Lacking the Plasminogen Activator Inhibitor 1 are Protected from Trabecular Bone Loss Induced by Estrogen Deficiency,”Journal of Bone and Mineral Research,15(8):1510-1516 (Nov. 8, 2000).
Glueck, C. J. et al., “Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study,”Fertility&Sterility, Jan. 2001, 75(1), 46-52.
Guzzo, P.R. et al., “Synthesis of a conformationally constrained threonin-valine dipeptide mimetic: design of a potential inhibitor of plasminogen activator inhibitor-1,”Tetrahedron Letters,43(1), 41-43 (2002).
Hamano, K. et al., “Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis,”American Journal of Kidney Diseases,Apr. 2002, 39(4), 695-705.
Hino, H., et al., “Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues,”Neuroscience Leters,Jan. 12, 2001, 297(2), 105-108.
Krishnamurti, C. et al., “Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits,”Blood,69(3): 798-803 (Mar. 1987).
Lahlou, A. et al., “Chronic graft dysfunction in renal transplant patients: potential role of plasminogen activator inhibitor type 1,”Transplantation,Apr. 27, 2002, 73(8), 1290-1295.
Levi, M. et al., “Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Experimental Thrombosis,”Circulation85, 305-312 (1992).
Malamas, M.S. et al. “Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties,”Journal of Medicinal Chemistry,Apr. 6, 2000, 43(7), 1293-1310.
Mari, D. P. et al., “Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease,”Thrombosis&Haemostasis,Feb. 1996, 75(2), 216-218.
Nordt, T. K. et al., “Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type I in Human Hepatic and Vascular Cells,”Journal of Clinical Endocrinology and Metabolism,85(4):1563-1568 (2000).
Razavi, M. K. et al., “Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy,”J. Endovascular Therapy,Oct. 2002, 9(5), 593-598.
Reilly, C. et al., “Both Circulating and Clot-Bound Plasminogen Activator-1 Inhibit Endogenous Fibrinolysis in the Rat,
Elokdah Hassan Mahmoud
Li David Zenan
McFarlane Geraldine Ruth
Baker Michael P.
McKane Joseph K.
LandOfFree
Substituted indole oxo-acetyl amino acetic acid derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted indole oxo-acetyl amino acetic acid derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indole oxo-acetyl amino acetic acid derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727293